BI chief “regrets” Brexit, but continues to invest in UKThe head of Germany’s Boehringer Ingelheim has said that he “regrets” Brexit, but reassured patients in the country Share XBI chief “regrets” Brexit, but continues to invest in UKhttps://pharmaphorum.com/news/bi-chief-regrets-brexit-but-continues-to-invest-in-uk/
Boehringer’s blockbuster Spiriva under pressure, profits downBoehringer Ingelheim has announced an increase in sales for full year 2018, but a slight decline in profits, Share XBoehringer’s blockbuster Spiriva under pressure, profits downhttps://pharmaphorum.com/news/boehringer-ingelheim-2018-sales-profits/
Boehringer files for new rare disease use for nintedanib in EU, USBoehringer Ingelheim has filed for a new use for its lung drug nintedanib in the US and Europe, Share XBoehringer files for new rare disease use for nintedanib in EU, UShttps://pharmaphorum.com/news/boehringer-files-for-new-rare-disease-use-for-nintedanib-in-eu-us/
AZ backs diabetes drug Farxiga with new cardio analysisAstraZeneca continues to make the case for its Farxiga diabetes drug, highlighting a cardiology analysis that it hopes Share XAZ backs diabetes drug Farxiga with new cardio analysishttps://pharmaphorum.com/news/az-backs-diabetes-drug-farxiga-with-new-cardio-analysis/
Boehringer follows Sanofi with job cuts in FranceBoehringer Ingelheim has confirmed it plans to axe more than 10% of its workforce in France, or more Share XBoehringer follows Sanofi with job cuts in Francehttps://pharmaphorum.com/news/boehringer-follows-sanofi-with-job-cuts-in-france/
Boehringer Ingelheim axes biosimilars development outside USBoehringer Ingelheim has said it has axed ex-US development of its biosimilars, focusing instead on getting its Humira Share XBoehringer Ingelheim axes biosimilars development outside UShttps://pharmaphorum.com/news/boehringer-ingelheim-axes-biosimilars-development-outside-us/
Google Ventures leads $45.4m investment in UK exosome biotech EvoxGoogle Ventures and US healthcare specialist Redmile were among a group of investors supporting a £35.5 million funding Share XGoogle Ventures leads $45.4m investment in UK exosome biotech Evoxhttps://pharmaphorum.com/news/google-ventures-leads-45-4m-investment-in-uk-exosome-biotech-evox/
Boehringer joins UK academics in battle against cystic fibrosisBoehringer Ingelheim (BI) and the UK Cystic Fibrosis Gene Therapy Consortium announced a global collaboration to develop a Share XBoehringer joins UK academics in battle against cystic fibrosishttps://pharmaphorum.com/news/boehringer-battles-against-cystic-fibrosis/
BI to trial SIRP drug with in-house PD-1 inhibitorBoehringer Ingelheim has revealed further details about its plans for a new kind of cancer immunotherapy licensed in Share XBI to trial SIRP drug with in-house PD-1 inhibitorhttps://pharmaphorum.com/news/bi-to-trial-sirp-drug-with-in-house-pd-1-inhibitor/
